Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Protein array-based companion diagnostics in precision medicine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. From next-generation sequencing to targeted treatment of non-acquired epilepsies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lessons learned from the implementation of non-invasive fetal RHD screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Thomas B G Poulsen
  • Azra Karamehmedovic
  • Christopher Aboo
  • Malene Møller Jørgensen
  • Xiaobo Yu
  • Xiangdong Fang
  • Jonathan M Blackburn
  • Claus H Nielsen
  • Tue W Kragstrup
  • Allan Stensballe
Vis graf over relationer

INTRODUCTION: The development of companion diagnostics (CDx) will increase efficacy and cost-benefit markedly, compared to the currently prevailing trial-and-error approach for treatment. Recent improvements in high-throughput protein technology have resulted in large amounts of predictive biomarkers that are potentially useful components of future CDx assays. Current high multiplex protein arrays are suitable for discovery-based approaches, while low-density and more simple arrays are suitable for use in point-of-care facilities.

AREA COVERED: This review discusses the technical platforms available for protein array focused CDx, explains the technical details of the platforms and provide examples of clinical use, ranging from multiplex arrays to low-density clinically applicable arrays. We thereafter highlight recent predictive biomarkers within different disease areas, such as oncology and autoimmune diseases. Lastly, we discuss some of the challenges connected to the implementation of CDx assays as point-of-care tests.

EXPERT OPINION: Recent advances in the field of protein arrays have enabled high-density arrays permitting large biomarker discovery studies, which are beneficial for future CDx assays. The density of protein arrays range from a single protein to proteome-wide arrays, allowing the discovery of protein signatures that may correlate with drug response. Protein arrays will undoubtedly play a key role in future CDx assays.

TidsskriftExpert Review of Molecular Diagnostics
Udgave nummer12
Sider (fra-til)1183-1198
Antal sider16
StatusUdgivet - dec. 2020

ID: 61864055